Emergent BioSolutions Inc.

Form 4

December 29, 2014

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

30(h) of the Investment Company Act of 1940

OMB 3235-0287

**OMB APPROVAL** 

Number:

January 31,

Expires:

2005

0.5

Estimated average burden hours per

response...

Check this box if no longer subject to Section 16. Form 4 or

**SECURITIES** Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue.

1(b).

See Instruction

(Print or Type Responses)

1. Name and Address of Reporting Person \* Abdun-Nabi Daniel

(7:m)

(Last) (First) (Middle)

2273 RESEARCH BLVD. SUITE 400

(State)

(Street)

2. Issuer Name and Ticker or Trading Symbol

Emergent BioSolutions Inc. [EBS]

3. Date of Earliest Transaction

(Month/Day/Year) 12/24/2014

Filed(Month/Day/Year)

4. If Amendment, Date Original

5. Relationship of Reporting Person(s) to

Issuer

below)

(Check all applicable)

\_X\_\_ Director 10% Owner X\_ Officer (give title Other (specify

President & CEO

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

ROCKVILLE, MD 20850

(City)

| (City)     | (State) (A          | Table Table        | I - Non-De | erivative S              | Securi  | ties Acqu  | ired, Disposed of               | , or Beneficiall | y Owned      |
|------------|---------------------|--------------------|------------|--------------------------|---------|------------|---------------------------------|------------------|--------------|
| 1.Title of | 2. Transaction Date | 2A. Deemed         | 3.         | 4. Securi                | ities A | cquired    | 5. Amount of                    | 6.               | 7. Nature of |
| Security   | (Month/Day/Year)    | Execution Date, if | Transactio | n(A) or D                | ispose  | d of (D)   | Securities                      | Ownership        | Indirect     |
| (Instr. 3) |                     | any                | Code       | Code (Instr. 3, 4 and 5) |         |            | Beneficially                    | Form: Direct     | Beneficial   |
|            |                     | (Month/Day/Year)   | (Instr. 8) | r. 8)                    |         |            | Owned                           | (D) or           | Ownership    |
|            |                     |                    |            |                          |         |            | Following                       | Indirect (I)     | (Instr. 4)   |
|            |                     |                    |            |                          | (A)     |            | Reported                        | (Instr. 4)       |              |
|            |                     |                    |            |                          | or      |            | Transaction(s) (Instr. 3 and 4) |                  |              |
|            |                     |                    | Code V     | Amount                   | (D)     | Price      | (IIISU. 3 aliu 4)               |                  |              |
| Common     | 12/24/2014          |                    | M/K        | 5,291                    | A       | \$ 18 0    | 159,330                         | D                |              |
| Stock (1)  | 12/24/2014          |                    | 1V1/ 1X    | 3,291                    | А       | Ф 10.9     | 139,330                         | D                |              |
| Commons    |                     |                    |            |                          |         | ¢          |                                 |                  |              |
|            | 12/24/2014          |                    | M/K        | 6,285                    | A       | φ<br>15 Ω1 | 165,615                         | D                |              |
| Stock (1)  |                     |                    |            |                          |         |            |                                 |                  |              |
| Common     | 10/04/0014          |                    | ГЛ         | 7.026                    | ь       | \$         | 150 270                         | Ъ                |              |
| Stock (1)  | 12/24/2014          |                    | F/K        | 7,236                    | D       | 27.64      | 158,379                         | D                |              |
| _          |                     |                    |            |                          |         |            |                                 |                  |              |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

**SEC 1474** (9-02)

### Edgar Filing: Emergent BioSolutions Inc. - Form 4

#### number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transaction<br>Code<br>(Instr. 8) | 5. Number mof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | Expiration Date  | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                 | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |  |
|---|---|--------------------------------------|---|---|--|------------------|--|-----------------|---|--|
|   |   |                                      |   | Code V                                  | (A) (D)  | Date Exercisable | Expiration<br>Date   | Title           | Amount<br>or<br>Number<br>of<br>Shares                              |  |
| Stock<br>Option                                     | \$ 18.9   | 12/24/2014                           |   | M/K                                     | 5,291  | 03/10/2010(2)    | 03/09/2016   | Common<br>Stock | 5,291   |  |
| Stock<br>Option                                     | \$ 15.91  | 12/24/2014                           |   | M/K                                     | 6,285  | 03/09/2011(3)    | 03/08/2017   | Common<br>Stock | 6,285   |  |

### **Reporting Owners**

| Reporting Owner Name / Address  | Relationships |           |                 |       |  |  |  |
|---|---------------|-----------|-----------------|-------|--|--|--|
| . 0   | Director      | 10% Owner | Officer         | Other |  |  |  |
| Abdun-Nabi Daniel<br>2273 RESEARCH BLVD. SUITE 400<br>ROCKVILLE, MD 20850 | X             |           | President & CEO |       |  |  |  |

## **Signatures**

/s/ Eric Burt, attorney-in-fact

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Consists of options granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.
- (2) The option vested in three equal installments in March 2010, 2011 and 2012.
- (3) The option vested in three equal installments in March 2011, 2012 and 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2